Kelun Overview

Kelun was founded in 1996 and now has evolved into a triangular operational platform comprised of Kelun Pharma, Chuanning Biotech, and Kelun-Biotech. Its total market value has exceeded one hundred billion RMB.In 2017, Kelun ranked 155th in China's top 500 manufacturing enterprises. In 2018, Kelun was awarded as Manufacturing Individual Champion Demonstration Enterprise by virtue of its global advantages in large volume injections. In 2023, Kelun ranked among the Top 3 in Chinese pharmaceutical manufacturing industry.

Sichuan Kelun Pharmaceutical Co., ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010. At the same time, Kelun immediately launched the industrial investment plan of RMB 10 billion and initiated the development strategy of "Three Driving Engines and Innovative Growth". "Engine No. 1" - Kelun maintains its leading position in the area of IV Solutions through continuous industrial upgrading and restructuring product portfolio; "Engine No. 2" - Kelun creates a competitive advantage in antibiotics from intermediate, APIs to FPPs by innovative exploitation of quality natural resources; "Engine No. 3" - Kelun strives for longevity through the elaboration of R&D systems and diversified technology innovation.

In the field of IV solution, Kelun has achieved comprehensive industrial upgrading by driving profitability through high-end manufacturing and new materials , and possesses the strategic advantages of technical innovations and quality benchmarks. Kelun has established a closed liability system from drug R&D, manufacturing, logistics to end use, which ensures product quality and safety. The leading products have been exported in batches to more than 50 countries and regions with high reputation. Kelun's independently developed Collapsible PP Bottle (Uniflex^®) with more than 20 patents, is an original invention both at home and abroad, and was awarded the State Science and Technology Advancement Award. Compared with traditional infusion, it boasts higher safety, cost-effective performance, and great application value in terms of less energy consumption and environment protection, representing the orientation of infusion products in China.  

Regarding the field of antibiotics, Kelun expanded to the west by founding Yili Chuanning Biotech Co., Ltd., producing erythromycin thiocyanate and cephalosporin series of intermediates. Through R&D tests, upgrading, optimization, innovative cooperation and introduction of advanced technology and equipment at home and abroad, Chuanning was approved to establish State Environmental Protection Engineering Center for Harmless Treatment and Resource Utilization of Antibiotic Residues, which solved the source issues of the antibiotic industry. In December 2022, Chuanning Biotech successfully went listed on the Shenzhen Stock Exchange GEM (Growth Enterprise Market) and fully entered into synthetic biology.    

Up to now, Kelun has applied for more than 1,300 patents and obtained more than 700 invention patent authorizations. It has successively started the research and development for more than 500 major drugs in the fields of oncology, bacterial infection, parenteral nutrition and other diseases. Since 2017, with more than 20 drugs approved every year, Kelun has become a leading enterprise of Chinese generic drugs. At the same time, more than ten innovative drug projects for the treatment of major diseases such as oncology, autoimmune diseases, inflammation, and metabolic diseases are in the clinical stage. Many clinical trials are global multicenter studies, and several projects are working with European and American partners to conduct global clinical research, which is carried out simultaneously in many countries including China, Europe, and the United States, in order to achieve synergistic effects of the pipelines and technical platform, and to maximize the global value of the pipelines. Kelun Biotech has successfully built an internationally renowned ADC research and development platform. In 2022, Kelun Biotech successfully signed three major authorized cooperation agreements with multinational giant Merck & Co., Inc., with a total contract value of over US$10 billion, which not only ranked first in the history of international authorization transactions in the Chinese pharmaceutical industry, but also ranked first gloriously as one of the TOP 10 Biopharma Partnerships of 2022 by total deal value in the global pharmaceutical industry. By taking such a move, Kelun has established the industry position of the leading team in the field of innovative drug research and development in China. In July 2023, Kelun Biotech was successfully listed on the Hong Kong Stock Exchange, marking the start of a new journey for Kelun’s innovative research and development and its global layout

With the enterprise purpose of "Exploring New Cures with Scientific and Ethical Excellence", Kelun has donated over RMB two hundred million to social public welfare causes, the Guangcai Program and charity causes, demonstrating Kelun's wealth values and sense of social responsibility, as well as an excellent private enterprise for its healthy development in market economy.